Thermo Fisher buys Novasep vaccine sites

LOGISTICS & INDUSTRIAL
Tim Harrup

Thermo Fisher Scientific has announced that it has completed the acquisition of Henogen S.A., Novasep’s viral vector manufacturing business in Belgium for approximately €725 million in cash. Thermo Fisher Scientific is an American company which acts as a supplier side partner to other scientific enterprises, in its own words helping them in ‘solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories’. For its part, Novasep, headquartered in Lyon and active in the same domain, says that its offering ‘includes process development services, purification equipment and turnkey processes, contract manufacturing and complex active molecule services for pharmaceutical, biopharmaceutical, fine chemical, food and functional ingredients as well as fermentation and chemical commodities industries’.

Where the current €725 million transaction is concerned, with two locations in Seneffe and Gosselies, Novasep’s viral vector business provides more than 7,000 square meters of clinical and commercial manufacturing capacity. Michel Lagarde, executive vice president of Thermo Fisher, explains the company’s thinking: “Novasep’s viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally. The addition of their manufacturing capabilities in Europe complements our four development and manufacturing sites in North America. In addition, they bring an incredibly talented team with more than two decades of experience across a broad range of viral vectors. The combination will benefit our global customers seeking support and capacity in the region as well as European customers bringing new medicines to patients inside and outside of Europe.”

Michel Spagnol, president and chief executive officer of Novasep adds: “Thermo Fisher is an outstanding partner for our viral vector business and its future development. Our diverse customer base will benefit from the combination of our viral vector services capabilities with the scale and capabilities of Thermo Fisher. Our talented employees will bring deep expertise to an organization that shares our commitment to providing ground-breaking new medicines to patients”.